Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
India · Delayed Price · Currency is INR | Market Cap | 4.29T +6.1% |
| Revenue (ttm) | 584.62B +11.2% |
| Net Income | 114.79B +5.0% |
| EPS | 47.80 +4.9% |
| Shares Out | 2.40B |
| PE Ratio | 37.45 |
| Forward PE | 32.42 |
| Dividend | 16.00 (0.89%) |
| Ex-Dividend Date | Feb 5, 2026 |
| Volume | 2,885,891 |
| Open | 1,794.20 |
| Previous Close | 1,796.50 |
| Day's Range | 1,766.50 - 1,800.00 |
| 52-Week Range | 1,548.00 - 1,916.60 |
| Beta | 0.10 |
| Analysts | Buy |
| Price Target | 2,039.91 (+13.97%) |
| Earnings Date | May 22, 2026 |
About NSE:SUNPHARMA
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, urology, dermatology, respira... [Read more]
Financial Performance
In fiscal year 2026, NSE:SUNPHARMA's revenue was 584.62 billion, an increase of 11.19% compared to the previous year's 525.78 billion. Earnings were 114.79 billion, an increase of 5.04%.
Financial StatementsAnalyst Summary
According to 34 analysts, the average rating for SUNPHARMA stock is "Buy." The 12-month stock price target is ₹2,040, which is an increase of 13.97% from the latest price.
News
Sun Pharma share price target: Brokerages remain positive on specialty growth and strong India business
Shares of Sun Pharmaceutical Industries remained in focus on Tuesday, May 27, with brokerages continuing to maintain a constructive outlook on the pharmaceutical major, driven by its specialty busines...
Sun Pharma To Present Long-Term Follow-up Data On UNLOXCYT
(RTTNews) - Sun Pharmaceutical Industries Limited (SUNPHARMA) said it will share updated results from the locally advanced cutaneous squamous cell carcinoma expansion cohort from the CK-301-101 trial ...
Pharma Sector Stocks Today, May 25: Torrent Pharma up 4.23%, Glenmark Pharma gains 4%, Sun Pharma down 0.31%
The pharmaceutical sector showed mixed performance on May 25, 2026, during the early morning trade. The broader market remained positive with the Nifty 50 rising 0.92% to 23,937.85 as of…
Sun Pharmaceutical Industries Transcript: Q4 25/26
Q4 FY 2026 saw 13.6% sales growth and strong gross margins, but EBITDA margin declined due to higher costs and lower milestone income. Innovative medicines and India business drove growth, while U.S. generics faced competition. Organon acquisition and new launches support future outlook.
Sun Pharmaceutical Industries Quarterly report: Q4 2026
Sun Pharmaceutical Industries has published its Q4 2026 quarterly earnings report on May 22, 2026.
Sun Pharma Q4 Results: Net profit rises 26.2% YoY, EBITDA grows over 6%
Sun Pharmaceutical Industries Ltd reported a strong set of Q4FY26 results, driven by healthy growth in its innovative medicines portfolio and steady expansion across global markets. For the quarter en...
Top Q4 results today, May 22: Sun Pharma, Hindalco Industries, Eicher Motors, Torrent Pharma, NTPC Green among key companies to announce earnings
A fresh set of companies is scheduled to announce their financial results for the quarter and financial year ended March 2026 on Friday, May 22. Key earnings announcements today include…
Sun Pharmaceuticals Industries Ltd (NSE:SUNPHARMA) Q4 2026 Earnings Report Preview: What to Expect
Sun Pharmaceuticals Industries Ltd (NSE:SUNPHARMA) Q4 2026 Earnings Report Preview: What to Expect
Why are Sun Pharma Advanced shares up over 14% today? Explained
Shares of Sun Pharma Advanced Research Company surged more than 14% on Monday after the company reported a sharp turnaround in its March quarter earnings, supported by exceptional gains and…
How Sun Pharma’s U.S. buy could spur other Indian pharma firms' global expansion
Kunal Dhamesha, Senior Analyst at Macquarie Capital, says Sun Pharma’s U.S. acquisition could encourage its peers to look beyond generics and pursue M&As in specialty and patented medicines, though ap...
Sun Pharma sees Rs 24 crore block deal as 139,060 shares change hands
Shares of Sun Pharmaceutical Industries remained largely flat in early trade on Tuesday, April 28, even as a block deal was executed in the stock. The shares were trading around…
Sun Pharma buys US-based Organon for $12 billion in biggest-ever overseas pharma deal
India's largest pharma company, Sun Pharma, has made its biggest overseas acquisition, buying Organon & Co for $11.8 billion. This deal significantly expands Sun Pharma's global presence and product r...
Gujarat’Sun Pharma to acquire Organon in $11.8bn all-cash deal
Ahmedabad: Homegrown pharma major Sun Pharmaceutical Industries Ltd on Monday announced it has signed a definitive agreement to acquire US-based Organ.
Stock Market Today, April 27: Organon Shares Surge After Sun Pharma Agrees to Acquire Company in All Cash Deal
Today, April 27, 2026, a jumbo all-cash buyout and merger-arb dynamics put Organon in focus.
Sun Pharma to Buy U.S. Healthcare Firm Organon in $11.75 Billion Deal
Sun Pharmaceutical (SUNPHARMA) Acquires Oganon for $11.75 Billion in Cash
Sun Pharmaceutical (SUNPHARMA) Acquires Oganon for $11.75 Billion in Cash
Indian Shares Climb On Firm Global Cues; Sun Pharma Shares Rally 7%
(RTTNews) - Indian shares rose notably on Monday, with mostly positive cues from global markets helping underpin sentiment.
Nifty 50 top gainers today, April 27: Sun Pharma, Jio Financial Services, Wipro, Reliance Industries and more
The benchmark indices ended higher on April 27, with the Nifty 50 closing at 24,092.70, up 194.75 points or 0.81%. The BSE Sensex gained 639.42 points or 0.83% to settle…
Why Is Organon Stock Skyrocketing Monday?
Sun Pharma to acquire Organon in an all-cash deal valued at $11.75 billion. OGN shares rise on the acquisition news. ... Full story available on Benzinga.com
Sun Pharmaceutical To Buy Organon For $11.75 Bln
(RTTNews) - Sun Pharmaceutical Industries Limited (SUNPHARMA, 524715), a major Indian pharma company, said on Monday that it has inked a deal to buy Organon & Co.(OGN) for $14 per share in cash with a...
Sun Pharma Acquires Organon & Co for $11.75 Billion
Sun Pharma Acquires Organon & Co for $11.75 Billion
Organon To Be Acquired By Sun Pharma In $11.75B Deal, OGN Stock Spikes Nearly 17% On Robinhood 24-Hour Market
Organon & Co. (NYSE: OGN) said on Sunday it signed a definitive agreement to be acquired by Sun Pharmaceutical Industries in an all-cash deal valued at $11.75 billion. According to the terms of the a...
Sun Pharma to acquire US-based Organon in $11.75bn deal
Indian pharmaceutical giant Sun Pharma is set to acquire US-based Organon & Co. for $11.75 billion in an all-cash deal. This landmark acquisition, one of India's largest overseas ventures, will propel...
Pharma sector stocks surge today, April 27: Sun Pharma jumps 6.62%, Aarti Drugs up 3.50%, Alembic Pharma rises 2.86%
Indian pharmaceutical stocks broadly advanced on Monday morning, with the Nifty Pharma Index rising 2.4% to 23,131.5. The S&P BSE Healthcare Index climbed 1.47% to 44,259.96, outperforming the broader...
Sun Pharma shares price jumps over 5% after $11.75 billion Organon acquisition deal announcement
Shares of Sun Pharmaceutical Industries Ltd jumped more than 5% in early trade after the company announced a major global acquisition deal involving Organon & Co. The transaction marks one…